https://scholars.lib.ntu.edu.tw/handle/123456789/458617
標題: | Impact of various treatment modalities on the outcome of stage IB1-IIA cervical adenocarcinoma | 作者: | YU-LI CHEN Ho C.-M. CHI-AN CHEN YING-CHENG CHIANG Huang C.-Y. CHANG-YAO HSIEH WEN-FANG CHENG |
公開日期: | 2011 | 卷: | 112 | 期: | 2 | 起(迄)頁: | 135-139 | 來源出版物: | International Journal of Gynecology and Obstetrics | 摘要: | Objective: To evaluate the outcomes of patients with stage IB1-IIA cervical adenocarcinoma treated by various modalities in order to formulate a better treatment strategy. Methods: The impact of various treatment modalities on the prognosis of 258 patients with stage IB1-IIA cervical adenocarcinoma was investigated. The therapeutic modalities included radical surgery (n = 174); radical surgery followed by adjuvant radiation therapy (RT), such as RT alone or concurrent chemo-radiotherapy (CCRT) (n = 46); or primary RT or CCRT (n = 38). Results: As compared with patients in the surgery-only group, patients with 1 postoperative major risk who underwent surgery followed by RT or CCRT had a significantly higher likelihood of disease relapse (2.3-fold, P = 0.041) and disease-related death (2.9-fold, P = 0.014). The likelihood of recurrence (P = 0.32) and death (P = 0.58) did not differ between patients who underwent adjuvant RT or CCRT for 1 major risk factor and those who underwent primary RT or CCRT. By contrast, patients with more than 1 major risk factor had a higher likelihood of disease recurrence (2.9-fold, P = 0.037) and disease-related death (3.4-fold, P = 0.051) than those who underwent primary RT or CCRT. Conclusion: Radical surgery is recommended for patients with stage IB1-IIA cervical adenocarcinomas without contraindications. Those with more than 1 postoperative pathologic risk factor had the worst prognosis despite adjuvant RT or CCRT. ? 2010 International Federation of Gynecology and Obstetrics. |
URI: | 2-s2.0-78650751467 https://scholars.lib.ntu.edu.tw/handle/123456789/458617 |
ISSN: | 0020-7292 | DOI: | 10.1016/j.ijgo.2010.08.016 | SDG/關鍵字: | antineoplastic agent; adenocarcinoma; adjuvant therapy; adult; article; cancer recurrence; cancer relapse; cancer staging; controlled study; female; human; major clinical study; mortality; priority journal; recurrent disease; risk factor; uterine cervix carcinoma |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。